Skip to content

Psilocybin and meditation: all studies

Page 3 of 4: studies 21 to 30 of 39, newest first. Back to the psilocybin and meditation overview

Research

Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.

Frontiers in Psychology 2023 Otto Simonsson, Cecilia U.D. Stenfors, Simon B. Goldberg et al. 4 citations

Previous research suggests that mindfulness meditation and psychedelic substances show promise as mental health interventions, but relatively little remains known about their potential impact on leadership outcomes. This study aimed to investigate if and how mindfulness meditation and psychedelic use may impact leadership among respondents with a management position as their primary role at...

Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals

Frontiers in Psychology October 5, 2022 Anna Søndergaard, Brice Ozenne, Sophia Armand et al. 35 citations

Background Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT 2A R) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in...

Psychedelics and mindfulness: A systematic review and meta-analysis

Journal of Psychedelic Studies September 16, 2022 Chelsea Radakovic, Ratko Radaković, Guy Peryer et al. 23 citations

Abstract Background and aims The benefits of classic serotonergic psychedelics (e.g. psilocybin, LSD, DMT, ayahuasca) are becoming more widely known with the resurgence in research in the past decade. Furthermore, the benefits of mindfulness are well documented. However, no systematic reviews have examined linkage of mindfulness and psychedelics use. The aim of this systematic review is to...

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Frontiers in Psychiatry July 7, 2022 Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al. 24 citations

Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. The main...

Don’t be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review

Neuroscience & Biobehavioral Reviews June 6, 2022 Corinna L. Felsch, Kim P. C. Kuypers 23 citations

BACKGROUND: Current first-line treatment for social anxiety disorder (SAD), one of the most prevalent anxiety disorders, is limited in its efficacy. Hence, novel treatment approaches are urgently needed. The current review suggests a combination of meditation-based interventions and the administration of a psychedelic as a future alternative treatment approach. While both separate treatments...

Psilocybin-Assisted Compassion Focused Therapy for Depression

Frontiers in Psychology March 25, 2022 Wendy T. M. Pots, Farid Chakhssi 31 citations

Psilocybin-assisted psychotherapy, i.e., psilocybin treatment with psychological support, has demonstrated the efficacy of psilocybin to reduce depressive symptoms. However, in clinical trials, the structure of psilocybin-assisted psychotherapy is primarily based on preparation, navigation (support during dosing sessions), and integration. For psychotherapeutic guidance, the application of this...

Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy

Frontiers in Psychology March 4, 2022 Agnieszka D. Sekula, Luke A. Downey, Prashanth Puspanathan 27 citations

Psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymethamphetamine (MDMA), has demonstrated promise in treatment of post-traumatic stress disorder (PTSD), anxiety, addiction, and treatment-resistant depression. Psychedelic-assisted psychotherapy (PP) represents a unique psychopharmacological model that...

Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

medRxiv March 2, 2022 Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al. preprint

Abstract Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in relatively low response rates (average range: 51 - 58%). Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy...

Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis

Journal of Humanistic Psychology June 12, 2021 Gabrielle Agin-Liebes, Eve Ekman, B. Anderson et al. 47 citations

The primary objective of this qualitative study was to explore the therapeutic trajectories of individuals undergoing psilocybin-assisted group therapy. This interpretive phenomenological analysis focused on an enriched study sample of gay-identified cisgender men ( n = 9) with human immunodeficiency virus diagnosed before 1996 and clinically significant trauma symptoms. Microphenomenological...

DOI: 10.1177/00221678211022949 (opens in new tab) Psilocybin Mindfulness Interpretative phenomenological analysis Psychotherapist +6

Psychedelics and health behaviour change

Journal of Psychopharmacology May 29, 2021 Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann et al. 87 citations

Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called ‘lifestyle diseases’—in personal suffering, premature mortality and public health costs—is considerable. Consequently, interventions designed...